Over the past few years, we’ve watched obesity medicines evolve from our favorite GLP-1 therapies we discuss like semaglutide, or dual agonists like tirzepatide, and now to triple agonists like retatrutide. Each generation has targeted more biological pathways than the last, and each has delivered greater weight loss by treating obesity as the complex b…